Recent advancements in anticancer therapies have led to the exploration of vascular-targeting agents like apatinib, anlotinib, and PD-1/PD-L1 immunotherapies in treating PAS, with promising results reported in several studies (22). This evidence concerns the gene CD274 and gonorrhea.